Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Investing Activities: 2018-2024

Historic Cash from Investing Activities for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to -$854.2 million.

  • Avidity Biosciences' Cash from Investing Activities fell 21.87% to -$587.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$309.4 million, marking a year-over-year increase of 58.13%. This contributed to the annual value of -$854.2 million for FY2024, which is 556.72% down from last year.
  • Avidity Biosciences' Cash from Investing Activities amounted to -$854.2 million in FY2024, which was down 556.72% from -$130.1 million recorded in FY2023.
  • Avidity Biosciences' 5-year Cash from Investing Activities high stood at -$7.8 million for FY2020, and its period low was -$854.2 million during FY2024.
  • In the last 3 years, Avidity Biosciences' Cash from Investing Activities had a median value of -$190.0 million in 2022 and averaged -$391.4 million.
  • In the last 5 years, Avidity Biosciences' Cash from Investing Activities tumbled by 3,212.77% in 2020 and then spiked by 31.53% in 2023.
  • Avidity Biosciences' Cash from Investing Activities (Yearly) stood at -$7.8 million in 2020, then plummeted by 959.95% to -$82.5 million in 2021, then plummeted by 130.20% to -$190.0 million in 2022, then skyrocketed by 31.53% to -$130.1 million in 2023, then slumped by 556.72% to -$854.2 million in 2024.